Burning Rock Biotech Limited (BNR) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BNR Revenue Growth
Revenue Breakdown (FY 2024)
BNR's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
BNR Revenue Analysis (2017–2024)
As of May 8, 2026, Burning Rock Biotech Limited (BNR) generated trailing twelve-month (TTM) revenue of $539.3 million, reflecting modest growth of +2.3% year-over-year. The most recent quarter (Q3 2025) recorded $131.6 million in revenue, down 11.4% sequentially.
Looking at the longer-term picture, BNR's 5-year compound annual growth rate (CAGR) stands at +6.2%, indicating steady revenue expansion. The company achieved its highest annual revenue of $563.2 million in 2022.
Revenue diversification analysis shows BNR's business is primarily driven by Service (56%), and Product (44%). With over half of revenue concentrated in Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including EXAS (+17.7% YoY), GH (+39.6% YoY), and NTRA (+35.9% YoY), BNR has underperformed the peer group in terms of revenue growth. Compare BNR vs EXAS →
BNR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BNRCurrent | $539M | +2.3% | +6.2% | -69.3% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 GH | $982M | +39.6% | +27.9% | -44.4% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 ACMR | $901M | +15.2% | +41.9% | 12.1% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% |
BNR Historical Revenue Data (2017–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $515.8M | -4.0% | $362.4M | 70.3% | $-357,559,000 | -69.3% |
| 2023 | $537.4M | -4.6% | $363.2M | 67.6% | $-669,321,000 | -124.5% |
| 2022 | $563.2M | +10.9% | $380.0M | 67.5% | $-980,407,000 | -174.1% |
| 2021 | $507.9M | +18.1% | $364.1M | 71.7% | $-797,064,000 | -156.9% |
| 2020 | $429.9M | +12.6% | $313.9M | 73.0% | $-412,405,000 | -95.9% |
| 2019 | $381.7M | +82.7% | $273.3M | 71.6% | $-169,092,000 | -44.3% |
| 2018 | $208.9M | +87.9% | $135.1M | 64.7% | $-161,396,000 | -77.3% |
| 2017 | $111.2M | - | $71.7M | 64.5% | $-120,867,000 | -108.7% |
See BNR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BNR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BNR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBNR — Frequently Asked Questions
Quick answers to the most common questions about buying BNR stock.
Is BNR's revenue growth accelerating or slowing?
BNR revenue growth slowed to +2.3%, below the 5-year CAGR of +6.2%. TTM revenue is $539M. The deceleration marks a shift from historical growth rates.
What is BNR's long-term revenue growth rate?
Burning Rock Biotech Limited's 5-year revenue CAGR of +6.2% reflects the variable expansion pattern. Current YoY growth of +2.3% is near this long-term average.
How is BNR's revenue distributed by segment?
BNR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.